Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 3/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 6/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28795245 | 0.96 | CRBN (0.47) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL28795207 | 0.94 | CRBN (0.47) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL28795192 | 0.94 | CDK9 (0.49) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL27163130 | 0.93 | CRBN (0.44) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL29976265 | 0.93 | CRBN (0.44) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL28795171 | 0.91 | CDK9 (0.51) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL31458460 | 0.91 | CDK9 (0.51) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL28795318 | 0.91 | CDK9 (0.51) | PLK4CRBNCDK9DDB1AR | |
| SCHEMBL28795206 | 0.91 | CRBN (0.54) | CRBNCDK9DDB1AR | |
| SCHEMBL28795252 | 0.91 | CRBN (0.49) | CRBNDDB1ARALKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805303-A | Molecule with double functions of degrading EGFR (epidermal growth factor receptor), composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2022-07-29 | — | — | CN | disclosed |